Amova Asset Management Americas Inc. Lowers Position in Recursion Pharmaceuticals, Inc. $RXRX

Amova Asset Management Americas Inc. cut its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 12.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,419,221 shares of the company’s stock after selling 801,804 shares during the period. Amova Asset Management Americas Inc.’s holdings in Recursion Pharmaceuticals were worth $16,583,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. International Assets Investment Management LLC bought a new stake in Recursion Pharmaceuticals during the fourth quarter worth $31,000. Allworth Financial LP grew its stake in Recursion Pharmaceuticals by 85.6% in the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after purchasing an additional 4,403 shares during the period. Sequoia Financial Advisors LLC purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $41,000. IFP Advisors Inc lifted its stake in Recursion Pharmaceuticals by 81.5% in the third quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock valued at $51,000 after purchasing an additional 4,650 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its stake in Recursion Pharmaceuticals by 28.1% in the second quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock valued at $56,000 after purchasing an additional 2,428 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 23,588 shares of Recursion Pharmaceuticals stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the sale, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at $7,789,349.68. The trade was a 1.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $3.96, for a total value of $158,400.00. Following the completion of the transaction, the director owned 6,218,287 shares of the company’s stock, valued at $24,624,416.52. The trade was a 0.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 131,937 shares of company stock valued at $486,974 over the last ninety days. 6.65% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

RXRX has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Morgan Stanley lifted their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. JPMorgan Chase & Co. lowered their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Finally, Wall Street Zen cut shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.10.

Recursion Pharmaceuticals Stock Down 1.7%

Shares of NASDAQ:RXRX opened at $2.89 on Tuesday. The firm has a fifty day moving average price of $3.32 and a two-hundred day moving average price of $3.59. The company has a market cap of $1.53 billion, a price-to-earnings ratio of -2.41 and a beta of 1.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47. Recursion Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The company had revenue of $6.47 million during the quarter, compared to analyst estimates of $15.78 million. During the same quarter in the previous year, the firm earned ($0.50) earnings per share. Recursion Pharmaceuticals’s revenue was down 56.8% on a year-over-year basis. Analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.